single species of glycopyrronium selected from the group of six compounds listed in claim 4. Further, the Examiner has required that we distinctly define any variable substituent groups required by the elected compound. If Group II is elected, the Examiner has required the further election of a single clinical condition from the group listed in claim 15.

Applicants respectfully note that pending claim 4 does not recite a list of glycopyrronium species, but does recite a list of ciclesonide compound structures.

ELECTION

Applicants hereby elect **Group I**, **drawn to claims 1-13 and 19**, without traverse. Further, as required by the Examiner, Applicants elect as the single species of ciclesonide from the list of ciclesonide compound structures listed in claim 4, [11β,16α-(R)]-16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy) pregna-1,4-dien-3,20-dion. Applicants also elect as the single species of glycopyrronium, the species exemplified in pending claim 8, in particular, (3R,2'R)-3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide, which substantially does not contain glycopyrronium in the S,S-, S,R- and/or R,S- forms.

Also, as required by the Examiner, Applicants identify the following claims that are readable on the elected species: **1-13 and 19**.

CONCLUSION

If the Examiner has any questions or wishes to discuss this matter, the Examiner is welcomed to telephone the undersigned attorney.

In the event this paper is not timely filed, Applicants petition for an appropriate extension of time. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 14-0112.

Respectfully submitted,

THE NATH LAW GROUP

Date: January <u>21</u>, 2009 THE NATH LAW GROUP 112 S. West Street Alexandria, VA 22314

Tel: (703) 548-6284 Fax: (703) 683-8396 Reg. No. 26,965 Sheldon M. McGee Reg. No. 50,454 Customer No. 34375